Drouin-OuelletJ., LauS., BrattåsP.L., Rylander OttossonD., PircsK., GrassiD.A., CollinsL.M., VuonoR., Andersson SjölandA., Westergren-ThorssonG., GraffC., MinthonL., ToressonH., BarkerR.A., JakobssonJ., and ParmarM. (2017). REST suppression mediates neural conversion of adult human fibroblasts via microRNA-dependent and -independent pathways. EMBO Mol. Med. 9, 1117–1131.
2.
ParmarM., BjörklundA., and BjörklundT. (2021). In vivo conversion of dopamine neurons in mouse models of Parkinson's disease—a future approach for regenerative therapy? Curr. Opin. Genet. Dev. 70, 76–82.
3.
ParmarM., GrealishS., and HenchcliffeC. (2020). The future of stem cell therapies for Parkinson disease. Nat. Rev. Neurosci. 21, 103–115.
4.
PfistererU., KirkebyA., TorperO., WoodJ., NelanderJ., DufourA., BjörklundA., LindvallO., JakobssonJ., and ParmarM. (2011). Direct conversion of human fibroblasts to dopaminergic neurons. Proc. Natl Acad. Sci. U. S. A. 108, 10343–10348.
5.
TorperO., PfistererU., WolfD.A., PereiraM., LauS., JakobssonJ., BjörklundA., GrealishS., and ParmarM. (2013). Generation of induced neurons via direct conversion in vivo. Proc. Natl Acad. Sci. U. S. A. 110, 7038–7043.
6.
TorperO., OttossonD.R., PereiraM., LauS., CardosoT., GrealishS., and ParmarM. (2015). In vivo reprogramming of striatal NG2 glia into functional neurons that integrate into local host circuitry. Cell Reports, 12, 474–481.
7.
VierbuchenT., OstermeierA., PangZ.P., KokubuY., SüdhofT.C., and WernigM. (2010). Direct conversion of fibroblasts to functional neurons by defined factors. Nature, 463, 1035–1041.
